Physician profile
Noaman Sanni
NPI 1982654901
$4,402.01
in general payments reported to CMS, 2019-2025
30 companies · $1,248 in 2025
The $1,248 reported for 2025 was more than what 82% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $317 · 2020: $510 · 2021: $494 · 2022: $757 · 2023: $365 · 2024: $712 · 2025: $1,248.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,309 · Education: $15.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,309.42 |
| Education | $15.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,079.30 | 2019-2025 | Hydrus Microstent, Rocklatan, Tryptyr |
| Allergan, INC. | $416.44 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $343.80 | 2023-2025 | Vyzulta, Miebo, Xiidra |
| Abbvie INC. | $286.78 | 2022-2025 | Durysta, Lumigan, Botox |
| Revance Therapeutics, INC. | $246.13 | 2024-2025 | Daxxify |
| Oyster Point Pharma, INC. | $234.17 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Biotissue Holdings INC. | $211.63 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $210.74 | 2019-2023 | |
| Tarsus Pharmaceuticals, INC. | $191.82 | 2024-2025 | Xdemvy |
| Mallinckrodt Hospital Products INC. | $173.58 | 2020-2025 | Acthar |
| Sight Sciences, INC. | $119.79 | 2019-2025 | Omni Surgical System, Sion Surgical Instrument |
| Johnson & Johnson Surgical Vision, INC. | $111.12 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $109.42 | 2022-2025 | Cequa |
| Ocular Therapeutix, INC. | $98.09 | 2024-2025 | Dextenza |
| Horizon Therapeutics Plc | $75.56 | 2019-2023 | Tepezza |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $68.16 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $52.35 | 2025 | Ultomiris |
| Harrow Eye, LLC | $47.27 | 2024 | Triesence, Iheezo, Vevye |
| Omeros Corporation | $45.38 | 2019 | |
| Amgen INC. | $44.96 | 2024-2025 | Tepezza |
| Galderma Laboratories, L.P. | $39.97 | 2020-2021 | |
| Ivantis, INC | $37.22 | 2020 | |
| Thea Pharma INC. | $23.51 | 2023 | |
| Spark Therapeutics, INC. | $23.08 | 2019 | |
| Solta Medical, A Division of Bausch Health US, LLC | $22.08 | 2024 | Clear+Brilliant |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $21.24 | 2020 | |
| Beaver-Visitec International, INC. | $20.15 | 2021 | |
| Astellas Pharma US INC | $18.52 | 2023 | |
| Merz Pharmaceuticals, LLC | $15.05 | 2025 | Xeomin |
| New World Medical,INC. | $14.70 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Noaman Sanni listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.